13F Holdings
中文EN

NNVC NANOVIRICIDES, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1379006 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.9%
TTM EPS YoY-8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-179.2%
ROA-135.9%
ROIC (approx.)-196.2%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets33.5%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$0$0$0$0—
R&D expense$4.71M$5.55M$5.44M$6.39M$5.78M
SG&A expense$3.60M$4.04M$3.08M$2.55M$2.33M
Operating income-$8.31M-$9.59M-$8.52M-$8.94M-$8.11M
Interest expense—$149$49,808$938$5,123
Pretax income-$8.22M———-$8.11M
Net income-$8.22M-$9.47M-$8.29M-$8.59M-$8.11M
EBITDA-$7.79M-$8.86M-$7.77M-$8.20M-$7.40M
EPS (basic)-0.41-0.63-0.70-0.74-0.70
EPS (diluted)-0.41-0.63-0.70-0.74-0.70
Weighted avg. shares (diluted)20.19M15.12M11.87M11.63M11.53M
Balance sheet
Cash & equivalents$2.79M$1.56M$4.80M$8.15M$14.07M
Current assets$3.16M$1.67M$4.97M$8.45M$14.42M
PP&E, net$6.40M$6.83M$7.51M$8.11M$8.69M
Intangibles$308,769$317,039$325,308$333,578$341,848
Total assets$9.87M$8.82M$12.82M$16.90M$23.49M
Current liabilities$1.19M$1.31M$1.36M$534,250$412,837
Total liabilities$1.20M$1.30M$1.36M$2.03M$412,837
Shareholders' equity$8.68M$7.52M$11.46M$14.87M$23.08M
Shares outstanding23.01M16.61M13.14M11.70M11.59M
Cash flow statement
Operating cash flow-$7.70M-$8.48M-$6.32M-$5.67M-$5.89M
Capital expenditure$84,317$56,964$156,560$151,712$324,348
Free cash flow-$7.78M-$8.54M-$6.47M-$5.82M-$6.22M
Investing cash flow-$84,317-$56,964-$156,560-$151,712-$324,348
Financing cash flow$9.02M$5.30M$3.12M-$94,788-$234,716
Depreciation & amortization$517,016$735,536$750,744$739,259$715,055
Stock-based compensation——$563$44,000—

Free plan shows the latest 5 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.